Kornimate/medical-research-clean huggingface dataset:
workplace-sponsored program to reduce obesity

Conditions: Obesity; Cardiovascular Diseases

Summary: the purpose of this study is to design a comprehensive nutrition and physical activity strategy to gain a broad understanding of the social and cultural role of food and physical activity among workers. perspectives on innovative interventions that are socially feasible and culturally acceptable will also be obtained. health lifestyle promotion interventions addressing portion control, healthy nutrition, and increasing physical activity will be tested.

background: broad, population-based approaches are needed to stop or reverse the rise in obesity prevalence. according to the world health organization, obesity prevention can be achieved by promoting a healthy diet and a physically active lifestyle. a partnership with the eastman kodak company has been developed to test a worksite intervention for obesity prevention in rochester, new york. design narrative: the overall goal of this study is to design a comprehensive nutrition and physical activity strategy based on participatory research to promote a healthy lifestyle and to stop the shift of the population body mass index (bmi) curve to the right. six pairs of worksites will be randomized to either an intervention or control group. two cross-sectional samples of employees within each worksite will be measured at baseline and at the end of the intervention.

Eligibility criteria:
inclusion criteria: * full-time employees in good health
adipose tissue inflammation in hfpef

Conditions: Heart Failure With Preserved Ejection Fraction; Obesity

Summary: to evaluate the role of adipose tissue inflammation in patients with heart failure with preserved ejection fraction (hfpef). patients undergoing coronary artery bypass grafting with hfpef and without heart failure will be included in this prospective study. epicardial, paracardial, paraaortic/paravascular, subcutaneous adipose tissue samples as well as myocardial tissue will be harvested during cardiac surgery. inflammatory patterns of these tissues and their relation to circulating markers will be investigated.

heart failure with preserved ejection fraction (hfpef) is a growing public health concern with an increasing incidence, high morbidity and mortality and no proven therapy to date. better characterization of individual pathophysiological implications is mandatory to develop effective therapeutic strategies or preventive programs. obesity is an important risk factor for the development of hfpef and also modulates its course possibly by its association with systemic inflammation. however, the role of adipose tissue (at) inflammation in the development, maintenance and functional impairments in hfpef has been under-investigated. dysfunctional at leads to a shift from a protective adipokine profile to an imbalanced production of pro-inflammatory, pro-oxidant and pro-fibrotic adipokines. besides depot specific paracrine effects, the overall secretory activity or endocrine effect of at can be evaluated in peripheral plasma. the investigators hypothesize that adipose inflammation distinguishes obese hfpef patients from obese patients without heart failure and that adipose tissue inflammation is a key driver the maintenance and development of hfpef and determines functional capacity. in addition the investigators hypothesize that the degree of myocardial inflammatory alterations is more closely related to epicardial tissue alterations than subcutaneous or visceral at tissue inflammation or peripheral adipokine profiles.

Eligibility criteria:
inclusion criteria: * hfpef: left ventricular ejection fraction ≥ 50%, nt-pro-bnp ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, left ventricular-hypertrophy or left atrial-dilatation), bmi ≥ 30kg/m² * non-hf patients: no history of heart failure, left ventricular ejection fraction \> 50% and nt-pro-bnp \<125ng/l exclusion criteria: * previous cardiac surgery / coronary intervention / myocardial infraction * acute coronary syndrome (serum levels of troponin t \>50 pg/ml) * left ventricular ejection fraction \< 50% * indication for concomitant valvular surgery * planned beating heart coronary bypass surgery * hemodynamic instability * contraindication for magnetic resonance imaging * pregnancy * age \< 18 years * no informed consent possible
long-term prognosis and quality of life in early rheumatoid arthritis patients treated by 2015 acr guideline (leland)

Conditions: Rheumatoid Arthritis

Summary: to focus on the real world treat-to-target rate of early rheumatoid arthritis patients who will be treated according to the 2015 american college of rheumatology guideline for the treatment of ra. to explore the factors which influence the treat-to-target outcome.

resent study showed that rapid progression of cartilage and bone damage could happen on the early state of ra patients, so the clinicians should try the best to stop the trend, such as early diagnosis, early treatment and treat-to-target. but only half of the ra patients could reach low disease activity in the whole world and about 10% in china. the investigators enroll early ra patients who are treated according to the 2015 american college of rheumatology guideline. the relevant data are collected and analyzed by the statistician including clinical data, imaging markers, blood samples and patient-reported outcomes every 3 months.

Eligibility criteria:
inclusion criteria: * ≥18 years, * be diagnosed with ra according to the 1987 or 2010 acr criteria, * in the course of the disease within 6 months, * fill out questionnaires by oneself, * fully understand the survey, agree to take part in the survey with signing the informed consent, and authority the researchers to expose and use his or her personal health information. exclusion criteria: * woman in pregnancy, lactation or plan to pregnant in the next 2 years, * before enter this study, the patient joint any other ra clinical study in the past 24 weeks, * according to the clinicians, one may not report his /or her life quality or the utilization of leading medical resources.

Keywords: rheumatoid arthritis prognosis
safety and efficacy study of transplantation of epcs to treat idiopathic pulmonary arterial hypertension

Conditions: Idiopathic Pulmonary Arterial Hypertension

Summary: experimental data suggest that transplantation of endothelial progenitor cells (epcs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs. in addition, clinical studies suggest that autogolous progenitor cells transplantation is feasible and safe in patients with ischemic disease. this study will investigate the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous epcs in patients with idiopathic pulmonary arterial hypertension.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic pulmonary arterial hypertension * in new york heart association (nyha) functional class ii to iii * a mean pulmonary artery pressure more than 30 mmhg on right heart catheterization * the ability to walk ≥50 m during a standardized 6-minute walk test. exclusion criteria: * pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, hiv infection, liver disease, nyha functional class iv, major bleeding requiring blood transfusion, diabetes, renal dysfunction, and evidence for malignant diseases were excluded
a study evaluating al-3778 in combination with peginterferon alpha-2a in chronic hepatitis b subjects

Conditions: Hepatitis B, Chronic

Summary: this is a phase 2a, multi-center, randomized, double-blind, placebo-controlled study evaluating the safety, efficacy, and pharmacokinetics (pk) of al-3778 in combination with peg-ifn in subjects with hepatitis b e antigen (hbeag) positive chb virus infection who are treatment-naïve. the study will consist of a screening phase , a double-blind treatment phase followed by treatment with peg-ifn alone, and a post-treatment follow-up phase. approximately 30 subjects to complete the study. eligible subjects will be randomized into 2 treatment arms in a 2:1 ratio (active:placebo) to receive one of the following treatments: * arm a: peg-ifn plus al-3778 (n=20) * arm b: peg-ifn plus matching placebo (n=10)


Eligibility criteria:
inclusion criteria: 1. a female subject must be of non-childbearing potential 2. subjects must have chb infection, documented by serologic profile consistent for chb infection at screening: 1. serum hbsag positive (for \>6 months) 2. serum igm anti-hbc negative 3. subjects are treatment-naïve and are serum hbeag positive with: 1. serum hbv dna \>=20,000 iu /ml at screening 2. hbsag \>250 iu/ml at screening 3. ≥2× upper limit of normal (uln) alt and ≤5× uln at screening exclusion criteria: 1. positive test for hepatitis a virus immunoglobulin, hepatitis delta antibody (ab), hepatitis c ab, human immunodeficiency virus (hiv) ab and/or evidence of clinically relevant active infection that would interfere with study conduct or its interpretation would also lead to exclusion. 2. positive test for anti-hbs antibodies and anti-hbe antibodies. 3. subjects must have low levels of liver fibrosis that is classified as metavir f0-f2 4. any history or current evidence of hepatic decompensation 5. subjects must have absence of hepatocellular carcinoma 6. subject with evidence of retinopathy on retinal fundus photographs 7. exclusions related to interferon use for the purposes of this study 8. subjects with one or more of the following laboratory abnormalities at screening 1. serum creatinine elevation \>1.0× uln 2. hemoglobin \<11 g/dl \[males\], \<10.5 g/dl \[females\] 3. platelet count \<125× 109 cells/l 4. absolute neutrophil count \<1.0× 109 cells/l 5. total bilirubin \>1.0× uln; unless known gilbert's disease or dubin-johnson syndrome 9. subjects having received an investigational agent or investigational vaccine, or having received a biological product within 12 weeks or 5 half-lives (whichever is longer) prior to baseline (first intake of study drugs).
oral contraceptives, insulin resistance and cardiovascular risk profile in pre-menopausal women

Conditions: Insulin Sensitivity; Cardiovascular Risk; Perimenopausal Disorder

Summary: birth control pills are the most commonly used method of birth control. the purpose of this research study is to examine whether birth control pills change heart disease risk and how the body handles blood sugar when given to different women.

the oral contraceptive pill is the most commonly used birth control method. it is debated whether the birth control pill affects how the body handles insulin and sugar, or whether the pill changes heart disease risk. the goal of this study is to evaluate whether certain factors, such as how the body processes hormones, and demographic factors (e.g. body weight and race), influence how the pill affects the handling of insulin and sugar, and heart health.

Eligibility criteria:
inclusion criteria: * premenopausal, regular-cycling women 18-35 years * either african-american or caucasian (african-american and caucasian women will be bmi-matched) * non-smoker. exclusion criteria: * diabetes * clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, and malignant disease * contraindications to oral contraceptive use (history of blood clots, heart attacks or stroke, vascular disease, coagulopathy, prolonged immobilization, breast cancer, migraine head-aches, major surgery within past 6 months, blood pressure \>160/100 mmhg, pregnancy or lactation) * use of hormonal contraceptives, glucose-lowering medications, anti-hyperlipidemic, anti-hypertensive or other vasoactive drugs within previous 3 months

Keywords: oral contraceptive birth control pill women healthy volunteer insulin sensitivity insulin resistance cardiovascular risk factors endothelial function estrogen metabolism racial difference glucose intolerance
randomized sizing and hemodynamic study mitroflow vs. magna

Conditions: Aortic Valve Disease

Summary: the purpose of this study is to compare sizing,implant techniques, and hemodynamics between the mitroflow pericardial aortic valve and the edwards magna heart valve.

comparisons of valve types are often made according to labeled valve sizes. there is growing evidence that in the majority of cases the actual sizer and valve dimensions vary from the labeled diameters, which may not be related to any hemodynamically meaningful dimension. the disagreement between the true valve dimensions and the labeled valve size may render comparisons based on labeled size meaningless

Eligibility criteria:
inclusion criteria: * patients who are indicated for implant with a bioprosthetic valve in the aortic position according to the current practice for valve selection at the center. exclusion criteria: * less than 18 years of age * emergency surgery * pre-existing valve prothesis in the aortic position * aortic root replacements or enlargements * active endocarditis

Keywords: aortic valve heart valve valve replacement valve disease
pharmacokinetics of elinogrel in healthy volunteers and patients with mild, moderate, and severe renal impairment

Conditions: Renal Impairment

Summary: the purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its metabolite in patients with mild, moderate, and severe renal impairment compared to healthy volunteers.

multiple-dose, open-label parallel-group design in patients with mild, moderate or severe renal impairment and age (±7 years), sex and weight (±15% bmi) matched healthy subjects. * mild renal impairment: crcl from 50 to ≤80 ml/min * moderate renal impairment: crcl from 30 to \<50 ml/min * severe renal impairment: crcl of \<30 ml/min

Eligibility criteria:
inclusion criteria: * able to understand and sign the written informed consent * subjects should have either normal renal function or have stable renal disease exclusion criteria: * history of heart disease * unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder

Keywords: elinogrel renal impairment healthy kidney dysfunction
multiplex respiratory pcr results in diabetic pneumonia cases

Conditions: Multiplex Respiratory PCR Results in Diabetic Pneumonia Cases

Summary: multiplex respiratory polymerase chain reaction (pcr) test has gained wide acceptance as an alternative to conventional culture methods for the detection of the causative agent of community-acquired pneumonia (cap). the aim of this study is to evaluate the positivity and to determine the causative agent of cap using multiplex respiratory pcr test in patients with diabetes mellitus.

a total of 151 adults diagnosed with cap were enrolled. group 1 composed of patients who had diabetes (n=42) and group 2 consisted of patients who did not have diabetes (n=109). demographic and clinical data of the subjects were collected and compared statistically. the multiplex respiratory pcr test positivity of group 1 was statistically higher than group 2 (p=0.004). the most identified nasopharyngeal pathogen was sarscov2 in group 1, whereas in group 2, the most prevalent agent was streptococcus pneumoniae (p=0.002, p=0.628). furthermore, the amount of procalcitonin, crp, neutrophil counts and the ratio of neutrophil-to-lymphocyte ratio (nlr) and crp-to-lymphocyte (clr) ratio on admission were statistically higher in group 1 than groups 2 (p=0.012, p=0.002, p\<\<0.001, p=0.001, p=0.001). diabetic patients are at greater risk for developing cap. therefore, early detection and prompt treatment is crucial for diabetic patients with cap to avoid morbidity and mortality. multiplex respiratory pcr test is an important method for identifying the causative agent of cap rapidly.

Eligibility criteria:
inclusion criteria: in this study, a population of 190 people over the age of 18 were searched in terms of suitability for this work , who diagnosed with cap after admission to the department of chest diseases by using a multiplex respiratory pcr test. exclusion criteria: subjects who had an infection other than pneumonia, and had a diagnosis of malignancy, transferred to intensive care unit and pregnant women were excluded.

Keywords: pneumonia, multiplex respiratory pcr test
idiopathic purpura fulminans associated with anti-ps antibodies in children

Conditions: Idiopathic Purpura

Summary: idiopathic purpura fulminans by anti-protein s antibody is a very rare but potentially extremely serious entity. the data in the literature are poor with only isolated report boxes and a single series of less than 10 boxes. the creation of a larger series of cases would make it possible to better understand this pathology and to offer assistance in diagnosis and management.


Eligibility criteria:
inclusion criteria: * diagnostic of idiopathic purpura fulminans * acquired protein s deficiency exclusion criteria: - other infecious purpura diagnosis

Keywords: protein s acquired deficiency idiopathic purpura fulminans
value of ca125 and yolk sac morphology in prediction of pregnancy outcome in threatened miscarriage

Conditions: Threatened Miscarriage in First Trimester

Summary: evaluation of serum ca125 level and yolk sac morphology in women with threatened miscarriage is very important to predict pregnancy outcome


Eligibility criteria:
inclusion criteria: * pregnant women between 20-40 years. pregnancy between 6-10 weeks. single intrauterine spontaneous pregnancy. vaginal bleeding or bloody vaginal discharge with or without pelvic pain for patients with threatened miscarriage. exclusion criteria: * medical disorders with pregnancy. history of recurrent miscarriage. any maternal disease that would cause an increase in ca125 level. local gynecological disorders e.g. fibroid. presence of any uterine malformation. history of congenital abnormalities in previous pregnancy presence of multiple pregnancy. presence of anembryonic sac. absent fetal heart pulsation.

Keywords: ca125 yolk sac morphology threatened miscarriage
cftr related pancreatitis study

Conditions: Cystic Fibrosis; CFTR Gene Dysfunction

Summary: the main causes of acute recurrent pancreatitis (arp) or chronic pancreatitis (cp) in children are defects in genes that have been associated to pancreatitis. among these gene defects cftr gene mutations are commonly found, 34% arp and 23% cp . since not every cftr gene mutations clinically manifest, just identifying these cftr gene mutations may not help to establish a clear role of this defect in the etiology of the individual arp/cp. the novel beta-adrenergic sweat secretion test is a very sensitive test to detect small abnormalities in cftr function in form of a linear gene-function relation. by identifying even mild cftr defects, in future will help in finding the role of cftr modulators and providing treatment to these patients.


Eligibility criteria:
inclusion criteria: * age : 4 years and older * diagnosis: acute recurrent pancreatitis or chronic pancreatitis * history: at least one of the following: 1. carry one or two cftr mutations 2. borderline sweat chloride levels 3. has family history of cf 4. has had positive cf newborn screening exclusion criteria: * pregnant females: will be excluded at screening.
correlation of length of index finger to vertical dimensions of occlusion for edentulous patients

Conditions: Patient Satisfaction; Dental Prosthesis; Edentulous Jaw

Summary: this study is a randomized clinical trial comparing the conventional method of recording occlusal vertical dimension using willis gauge from the base of the nose to the base of the chin with the other method using vernier caliper for the length of the index finger to access the satisfaction level of edentulous patients acquiring complete dentures.

this study was to apply the anthropometric methods to correlate the length of fingers to occlusal vertical dimensions and also by using the willis method to assess the occlusal vertical dimension for edentulous patients and assess satisfaction by comparing both the methods for patients who are in the process of acquiring complete dentures. furthermore, conventional methods are applied most commonly for the recording of occlusal vertical dimensions. this study also bridged the knowledge gap among clinicians to adapt to a different methodology for recording the vdo using the anthropometric measurement of fingers which would improve denture satisfaction. therefore, a total of 71 patients were selected for this study, having lost their ovd due to the complete absence of teeth and having no history of maxillofacial or orthognathic surgery, nor any skeletal deformities or disfigurement of fingers. the measurements were made at the appointment for jaw relations records in which the length of the fingers was measured with a digital vernier caliper and also the conventional methods were applied for recording the occluding vertical dimensions which included recording the distance from the base of the nose septum (subnasion - sn) to the base of the chin (menton - me) (sn-me). the length of the index finger (2d) was recorded and a correlation was found between sn-me and finger length.

Eligibility criteria:
inclusion criteria: * completely edentulous patients * patients willing to participate in the study * male patients without a beard exclusion criteria: * partially dentate patients * patients having any maxillofacial or myofascial disorders * any history of orthognathic or orthodontic surgery * deformities or disfigurement of fingers * patients with neurological problems in the head and neck * any bony defects or visible sharp spicules * nose or chin deformity * tmj disorders (intracapsular/extracapsular) * heavy bulky chin area (double chin)

Keywords: occlusal vertical dimension, edentulous patients,
permixon® in luts evaluation study (perles)

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: the aim of this study is to support the efficacy of permixon 160 mg b.i.d. in treating subjects with symptomatic benign prostatic hyperplasia (bph), compared to placebo, using tamsulosine lp 0.4 mg as a reference treatment.


Eligibility criteria:
inclusion criteria: * male subject * between 45 and 85 years old * subject with bothersome lower urinary tract symptoms (luts) due to bph such as frequency (daytime or night time), urgency, sensation of incomplete voiding, delayed urination or weak stream * subject naive to any prior treatment for luts due to bph * prostate enlargement at digital rectal examination (dre) suggestive of bph * i-pss \> 12 at enrolment visit and at inclusion visit * qol i-pss score ≥ 3 evaluated at enrolment visit and at inclusion visit exclusion criteria: * urological history such as urethral stricture disease and/or bladder neck disease, active (at enrolment and/or inclusion or recurrent urinary tract infection, stone in bladder or urethra) * any neurologic or psychiatric disease/disorder interfering with detrusor or sphincter muscle * insulin-dependent diabetes mellitus and non-controlled non insulin-dependent diabetes mellitus * known severe renal insufficiency or creatinine clearance \< 30 ml/mn * known liver insufficiency or clinically significant abnormal liver function tests * history of, or concomitant, cardiac arrhythmia or angina pectoris * orthostatic hypotension at enrolment or inclusion visit * known hypersensitivity to one of the constituents of the study drugs * is participating in another clinical trial